FR2321892A1 - Preparations pharmaceutiques pour l'administration orale renfermant un ester-17b de nandrolone et nouveaux esters-17b de nandrolone - Google Patents

Preparations pharmaceutiques pour l'administration orale renfermant un ester-17b de nandrolone et nouveaux esters-17b de nandrolone

Info

Publication number
FR2321892A1
FR2321892A1 FR7625795A FR7625795A FR2321892A1 FR 2321892 A1 FR2321892 A1 FR 2321892A1 FR 7625795 A FR7625795 A FR 7625795A FR 7625795 A FR7625795 A FR 7625795A FR 2321892 A1 FR2321892 A1 FR 2321892A1
Authority
FR
France
Prior art keywords
nandrolone
esters
ester
new
oral administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7625795A
Other languages
English (en)
Other versions
FR2321892B1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo NV
Original Assignee
Akzo NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo NV filed Critical Akzo NV
Publication of FR2321892A1 publication Critical patent/FR2321892A1/fr
Application granted granted Critical
Publication of FR2321892B1 publication Critical patent/FR2321892B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
FR7625795A 1975-08-27 1976-08-26 Preparations pharmaceutiques pour l'administration orale renfermant un ester-17b de nandrolone et nouveaux esters-17b de nandrolone Granted FR2321892A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL7510104A NL7510104A (nl) 1975-08-27 1975-08-27 Werkwijze ter bereiding van een oraal werkzaam farmaceutisch preparaat.

Publications (2)

Publication Number Publication Date
FR2321892A1 true FR2321892A1 (fr) 1977-03-25
FR2321892B1 FR2321892B1 (fr) 1979-05-25

Family

ID=19824362

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7625795A Granted FR2321892A1 (fr) 1975-08-27 1976-08-26 Preparations pharmaceutiques pour l'administration orale renfermant un ester-17b de nandrolone et nouveaux esters-17b de nandrolone

Country Status (17)

Country Link
US (1) US4083973A (fr)
JP (1) JPS5231063A (fr)
AU (1) AU508727B2 (fr)
BE (1) BE845613A (fr)
CA (1) CA1092025A (fr)
DE (1) DE2638507A1 (fr)
FR (1) FR2321892A1 (fr)
GB (1) GB1563302A (fr)
GR (1) GR70296B (fr)
HU (1) HU176743B (fr)
IE (1) IE44533B1 (fr)
IL (1) IL50274A (fr)
LU (1) LU75648A1 (fr)
NL (1) NL7510104A (fr)
NZ (1) NZ181865A (fr)
PH (1) PH12363A (fr)
ZA (1) ZA764868B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0005121A2 (fr) * 1978-04-25 1979-10-31 Pharmaceutical Licences Company Ltd. Procédé de stabilisation de 4-methyl-5-(2'chlorethyl)-thiazol
FR2427100A1 (fr) * 1978-06-02 1979-12-28 Kali Chemie Pharma Gmbh Composition pharmaceutique a propriete de resorption amelioree et procede pour sa fabrication

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0177342A3 (fr) * 1984-10-04 1987-12-02 Genentech, Inc. Formulations orales de protéines thérapeutiques
US5140021A (en) * 1986-04-16 1992-08-18 Genesis Systems Corporation Method and dosage form for treatment of premenstrual syndrome
US5208032A (en) * 1988-07-15 1993-05-04 Rutgers, The State University Of New Jersey Increasing the growth of turkeys using implant of 19-nortestosterone
ATE333867T1 (de) * 1994-03-18 2006-08-15 Shire Lab Inc Emulgierte arzneistoffabgabesysteme
US5824638A (en) * 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US6011027A (en) * 1999-02-18 2000-01-04 Lpj Research, Inc. Use of 19-nor-4-androstenediol to increase 19-nortestosterone levels in humans
US6652880B1 (en) 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
JP4995407B2 (ja) 2002-04-25 2012-08-08 バナー ファーマキャップス， インコーポレーテッド 咀嚼可能なソフトカプセル
GB0304927D0 (en) * 2003-03-04 2003-04-09 Resolution Chemicals Ltd Process for the production of tibolone
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
EP1530965B1 (fr) 2003-11-11 2006-03-08 Mattern, Udo Composition à liberation prolongée pour application nasale comprenant des hormones sexuelles
CN1257711C (zh) * 2003-12-05 2006-05-31 石药集团中奇制药技术（石家庄）有限公司 丁苯酞软胶囊及其制备工艺
US20060140820A1 (en) 2004-12-28 2006-06-29 Udo Mattern Use of a container of an inorganic additive containing plastic material
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
AU2006299833B2 (en) 2005-10-12 2012-04-12 Besins Healthcare Luxembourg Sarl Improved testosterone gel and method of use
MX2009003654A (es) 2006-10-04 2009-04-22 M & P Patent Ag Sistema de suministro por liberacion controlada para la aplicacion nasal de neurotransmisores.
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
CA2950670A1 (fr) 2014-06-17 2015-12-23 Merck Sharp & Dohme B.V. Formulations stables d'undecanoate de testosterone

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE675379A (fr) * 1965-01-26 1966-05-31
FR2262527A1 (fr) * 1974-02-28 1975-09-26 Akzo Nv

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2998423A (en) * 1958-02-25 1961-08-29 Organon Esters of 19-nortestosterone
US3016388A (en) * 1959-06-30 1962-01-09 Organon New esters of 19-nor-testosterone

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE675379A (fr) * 1965-01-26 1966-05-31
FR2262527A1 (fr) * 1974-02-28 1975-09-26 Akzo Nv

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE MERCK INDEX, 8EME EDITION, 1968, MERCK & CO, RAHWAY, N.J., (U.S.A.) *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0005121A2 (fr) * 1978-04-25 1979-10-31 Pharmaceutical Licences Company Ltd. Procédé de stabilisation de 4-methyl-5-(2'chlorethyl)-thiazol
EP0005121A3 (en) * 1978-04-25 1979-11-28 Pharmaceutical Licences Company Ltd. Stabilisation process
FR2427100A1 (fr) * 1978-06-02 1979-12-28 Kali Chemie Pharma Gmbh Composition pharmaceutique a propriete de resorption amelioree et procede pour sa fabrication

Also Published As

Publication number Publication date
IL50274A (en) 1980-11-30
CA1092025A (fr) 1980-12-23
BE845613A (fr) 1977-02-28
DE2638507A1 (de) 1977-03-03
IE44533B1 (en) 1981-12-30
LU75648A1 (fr) 1977-03-31
HU176743B (en) 1981-05-28
IL50274A0 (en) 1976-10-31
AU508727B2 (en) 1980-04-03
FR2321892B1 (fr) 1979-05-25
AU1698076A (en) 1978-02-23
JPS5231063A (en) 1977-03-09
ZA764868B (en) 1977-07-27
NZ181865A (en) 1978-12-18
GR70296B (fr) 1982-09-06
PH12363A (en) 1979-01-29
IE44533L (en) 1977-02-27
GB1563302A (en) 1980-03-26
US4083973A (en) 1978-04-11
NL7510104A (nl) 1977-03-01

Similar Documents

Publication Publication Date Title
FR2321892A1 (fr) Preparations pharmaceutiques pour l'administration orale renfermant un ester-17b de nandrolone et nouveaux esters-17b de nandrolone
BE849632A (fr) Composition pharmaceutique pour l'administration orale
BE842329A (fr) Nouveaux esters-17b d'oestradiol et compositions therapeutiques renfermant des esters-17b d'oestradiol
FR2523443B1 (fr) Nouvelles formulations pharmaceutiques contenant le coenzyme q10 adaptees pour l'administration topique
FR2430410B1 (fr) Phenethanolamines et compositions pharmaceutiques en contenant
FR2314731A1 (fr) Azacycloalcan-2-ones 1-substituees et compositions pharmaceutiques contenant ces composes a titre d'excipients
BE843140A (fr) Aazacycloalcan-2-ones 1-substituees et compositions pharmaceutiques contenant ces composes a titre d'excipients
BE855032A (fr) Compositions pharmaceutiques pour opacification barytee et leur procede de preparation
NZ182190A (en) Clavulanic acid derivatives and pharmaceutical compositions
DK152333C (da) Indretning til oral indgivelse til droevtyggere
PT65244A (en) Pharmaceutically active complexes and pharmaceutical compositions containing them
NZ190842A (en) 4-substituted-thiazole-2-oxamic acids and esters and pharmaceutical compositions
ZA772514B (en) Improvements relating to the administration of pharmaceutically active substances to animals
BE864124A (fr) Compositions pharmaceutiques analgesiques et anti-inflammatoires
NZ184408A (en) 16-s-acyl derivatives of 16-deacetoxy-fusidic acid and pharmaceutical compositions
NZ182046A (en) 9-0-ethers of clavulanic acid,saltd and esters and pharmaceutical compositions
FI792303A (fi) Farmaceutisk komposition foer rektal administration av kefalosporin
FR2315910A1 (fr) Compositions pharmaceutiques contenant de la " debrycine " heterocolloidale et procede pour leur preparation
BE872647A (fr) Composition pharmaceutique administrable par voie orale
FR2337139A1 (fr) Esters d'acides mercaptodicarboxyliques organo-stanniques et compositions en renfermant
GB2025224B (en) Pharmaceutical compositions comprising trimethoprim and n ethyl pyridone 3 carboxylic acid derivatives
IL52952A0 (en) New hydroxymethyl-pyridine esters their preparation and pharmaceutical compositions containing them
FR2336389A1 (fr) Esters d'acides thiol-carboxyliques et leur preparation
BE881625A (fr) Esters o-alcoxycarbonyl-phenyliques d'un acide anthranilique leur preparation et compositions pharmaceutiques en contenant
BE848975A (fr) Preparations pharmaceutiques contraceptive

Legal Events

Date Code Title Description
ST Notification of lapse